Early pregnancy biomarkers of inflammation and metabolic regulation in polycystic ovary syndrome
The Journal of Clinical Endocrinology & Metabolism · 15.07.2026 · 111 (8) · e1961-e1972
DOI: 10.1210/clinem/dgag098 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 09.03.2026. Verfasst von Simon Alesi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Monash Centre for Health Research and Implementation (MCHRI), Monash University, Clayton, VIC 3168, Australia. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Biomarkers, Inflammation, Diabetes, Gestational. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Region Örebro Research Committee, Medical Scientific Fund of the Mayor of Vienna.
Abstract (Originalsprache)
Objective
To profile biomarkers of inflammation and metabolic regulation in early pregnancy among women with and without polycystic ovary syndrome (PCOS), and to assess whether these biomarkers influence the relationship between PCOS and adverse maternal or neonatal outcomes.
Design
Cross-sectional study with interaction analyses using pooled baseline data from 2 international multicenter clinical trials. Subjects One hundred and fifty-one pregnant women (at <24 weeks’ gestation) at risk of gestational diabetes mellitus, including 65 with PCOS and 86 without PCOS. Main outcome measures Early pregnancy markers of inflammation and metabolic regulation were assessed, including C-reactive protein, tumor necrosis factor-α, interleukins, monocyte chemoattractant protein-1 (MCP1), fatty acid binding protein-4 (FABP4), growth differentiation factor-15, and adipokines (total adiponectin, leptin, resistin, chemerin, vaspin, and cathepsin-S). Biomarkers differing by PCOS status were further examined for interaction effects on maternal and neonatal outcomes.
Results
Monocyte chemoattractant protein-1 concentrations were 15% higher in women with PCOS compared with those without (geometric mean ratio [GMR]: 1.15; 95% CI: 1.01, 1.31; P & .04), but this association was attenuated after adjustment for maternal age and body mass index (BMI). Early pregnancy FABP4 concentrations were 32% higher in women with PCOS compared with those without (GMR: 1.32; 95% CI: 1.04, 1.68; P & .02), and this association remained significant after adjustment for maternal age (GMR: 1.34; 95% CI: 1.05-1.71; P & .02), but was attenuated after adjustment for BMI. No other biomarkers differed by PCOS status, and MCP1 or FABP4 showed no interactions with maternal or neonatal outcomes.
Conclusion
Monocyte chemoattractant protein-1 and FABP4 concentrations were elevated in early pregnancy among women with PCOS, largely reflecting maternal adiposity. These markers did not modify associations between PCOS and pregnancy outcomes. Larger longitudinal studies are needed to clarify underlying inflammatory and metabolic pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Monash Centre for Health Research and Implementation (MCHRI), Monash University, Clayton, VIC 3168, Australia.
- The Ritchie Centre, Hudson Institute of Medical Research and Department of Obstetrics and Gynaecology, Monash University, Clayton, Melbourne, VIC 3168, Australia.
- Department of Diabetes, Monash Health, Clayton, Melbourne, VIC 3168, Australia.
- School of Agriculture and Food Science, University College Dublin, Belfield, Dublin, Ireland.
- UCD Perinatal Research Centre, School of Medicine, University College Dublin, National Maternity Hospital, Dublin, Ireland.
- Macarthur Clinical School, Western Sydney University, Campbelltown, NSW 2560, Australia.
ORCID-Profile: Simon Alesi, Sharleen O'Reilly, David Simmons, Aya Mousa
Förderung
- National Health and Medical Research Council
- Region Örebro Research Committee
- Medical Scientific Fund of the Mayor of Vienna
- South Western Sydney Local Health District Academic Unit
- Western Sydney University Ainsworth Trust Grant
- European Union Commission Horizon 2020
- University College Dublin
- Graduate Research Scholarships
Zitieren
APA
Alesi, S., Mason, T., Ellery, S. J., Rassie, K., Neven, A. C. H., Belsti, Y., Jona, E., O'Reilly, S., Simmons, D., Teede, H., Mousa, A., IMPACT DIABETES B2B&ME, & TOBOGM Study Groups (2026). Early pregnancy biomarkers of inflammation and metabolic regulation in polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism, 111(8), e1961-e1972. https://doi.org/10.1210/clinem/dgag098
Vancouver
Alesi S, Mason T, Ellery SJ, Rassie K, Neven ACH, Belsti Y, et al. Early pregnancy biomarkers of inflammation and metabolic regulation in polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism. 2026;111(8):e1961-e1972. doi:10.1210/clinem/dgag098
BibTeX
@article{Alesi2026,
author = {Alesi, Simon and Mason, Taitum and Ellery, Stacey J and Rassie, Kate and Neven, Adriana C H and Belsti, Yitayeh and Jona, Eveline and O'Reilly, Sharleen and Simmons, David and Teede, Helena and Mousa, Aya and IMPACT DIABETES B2B&ME, IMPACT DIABETES B2B&ME and TOBOGM Study Groups, TOBOGM Study Groups},
title = {Early pregnancy biomarkers of inflammation and metabolic regulation in polycystic ovary syndrome},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
volume = {111},
number = {8},
pages = {e1961--e1972},
doi = {10.1210/clinem/dgag098}
}
EUVIMED